Vedanta Biosciences said it significantly reduced headcount to concentrate remaining resources on VE303, its lead live‑biotherapeutic bacterial consortium for prevention of recurrent Clostridioides difficile infection. The company signaled a laser focus on completing a planned Phase 3 trial, targeting a mid‑2027 readout to support potential approval pathways following positive Phase 2 data cited by management. Vedanta acknowledged prior program setbacks—halting other bacterial assets after negative Phase 2 results—and cited a prior 2023 $107 million Series C as the last major funding infusion. The staffing actions reflect a common biotech re‑set when companies pivot to prioritize a single late‑stage program under constrained financing. Analysts said VE303’s path follows the market precedent established by approved microbiome therapy Vowst (Seres), and success would validate the oral bacterial consortium approach. Failure or further delays could force broader restructuring or the search for partnership capital.